This article is more than 5 years old. Information may no longer be current.
8 IBD updates from ACG, UEG Week
Click Here to Manage Email Alerts
Several developments in inflammatory bowel disease were presented at the two major gastroenterology conferences last month: the American College of Gastroenterology Annual Scientific Meeting in Las Vegas and the United European Gastroenterology Week in Vienna.
In case you missed it, Healio Gastroenterology has compiled eight important highlights of IBD research presented at these conferences.
1. Remicade prevents serious infection, longer hospitalization in UC patients vs. Humira
LAS VEGAS — Patients with ulcerative colitis treated with Remicade were more likely to not experience serious infection or longer hospitalization compared with patients treated with Humira, according to a presentation given at ACG 2016 by Siddharth Singh, MD, MS, of the University of California San Diego. Read more
2. NOR-SWITCH: Switching to Remicade biosimilar safe, noninferior
Switching to biosimilar Remicade was safe and noninferior to continued treatment with the originator product across multiple indications, including IBD, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and chronic plaque psoriasis, according to data from the NOR-SWITCH study presented at UEG Week 2016. Read more
3. VIDEO: Rubin discusses new biosimilar data, Inflectra announcement
LAS VEGAS — In this exclusive video from ACG 2016, David T. Rubin, MD, FACG, professor of medicine at University of Chicago Medicine, discusses Pfizer’s announcement that Inflectra, its biosimilar to Remicade (infliximab, Janssen), will soon be available in the U.S. Watch now
4. Ozanimod shows long-term improvement for UC patients
LAS VEGAS — Ozanimod therapy showed long-term efficacy through improved Mayo score, and decreased incidence of rectal bleeding and stool frequency in patients with moderate-to-severe ulcerative colitis, according to data from the TOUCHSTONE trial presented at ACG by William J. Sandborn, MD, professor of medicine, chief of the division of gastroenterology and director of University of California San Diego Inflammatory Bowel Disease Center. Read more
5. Xeljanz induces remission, early response predicts efficacy in UC
LAS VEGAS — Xeljanz as induction therapy for patients with moderate-to-severe ulcerative colitis led to remission as early as 2 weeks; the early response rates correlated with efficacy results at 8 weeks, according to data from the OCTAVE induction trials presented during a plenary session at ACG 2016. Read more
6. Patient-centered IBD home reduces expenditures, improves QOL
LAS VEGAS — The institution of a patient-centered medical home for patients with inflammatory bowel disease resulted in less visits to the ED, less hospitalizations and overall improved quality of life in the first year, according to a presenter at ACG 2016. Read more
7. Mongersen trial shows positive results for Crohn's patients
Interim results from a phase 1b trial show that 12-week treatment with mongersen resulted in endoscopic improvement and clinical response and remission in patients with active Crohn’s disease, the manufacturer announced in a press release in September.
Since then, full trial results were presented at UEG Week 2016. Read more
8. COLLECT: Cobitolimod induces remission in both moderate, severe UC
Cobitolimod induced clinical remission in patients with both moderate and severe ulcerative colitis, according to data from a post-hoc analysis of the COLLECT study presented at UEG Week 2016. Read more